Review
The gut microbiota in anxiety and depression – A systematic review

https://doi.org/10.1016/j.cpr.2020.101943Get rights and content

Highlights

  • Review summarized studies characterizing gut microbiota in anxiety/depression.

  • Anxiety/depressive disorders were characterised by higher pro-inflammatory species.

  • Anxiety/depression had lower abundance of short-chain fatty acid producing-species.

  • Alpha and beta diversity findings were inconsistent.

  • Future research should assess diet, psychotropics and examine species' function.

Abstract

Growing evidence indicates the community of microorganisms throughout the gastrointestinal tract, (i.e., gut microbiota), is associated with anxiety and depressive disorders. We present the first systematic review of the gut microbiota in anxiety disorders, along with an update in depression. Consideration of shared underlying features is essential due to the high rates of comorbidity. Systematic searches, following PRISMA guidelines, identified 26 studies (two case-control comparisons of the gut microbiota in generalised anxiety disorder, 18 in depression, one incorporating both anxiety/depression, and five including symptom-only measures). Alpha and beta diversity findings were inconsistent; however, differences in bacterial taxa indicated disorders may be characterised by a higher abundance of proinflammatory species (e.g., Enterobacteriaceae and Desulfovibrio), and lower short-chain fatty acid producing-bacteria (e.g., Faecalibacterium). Several taxa, and their mechanisms of action, may relate to anxiety and depression pathophysiology via communication of peripheral inflammation to the brain. Although the gut microbiota remains a promising target for prevention and therapy, future research should assess confounders, particularly diet and psychotropic medications, and should examine microorganism function.

Introduction

Anxiety and depressive disorders are ubiquitous and debilitating psychiatric conditions that collectively affect close to 10% of the global population every year (World Health Organization, 2017). The World Health Organization (2019) estimates the global loss in productivity due to anxiety and depressive disorders amounts to $1 trillion USD annually – a trajectory expected to rise (Doran & Kinchin, 2019). Although engagement with psychotherapeutic and psychotropic treatments has increased over the past several decades (Olfson, Druss, & Marcus, 2015; Stephenson, Karanges, & McGregor, 2012), the prevalence and burden of anxiety and depressive disorders remains unchanged (Jorm, Patten, Brugha, & Mojtabai, 2017). Furthermore, there is substantial variation in response to existing treatments, which are overall efficacious in less than half of diagnosed patients (Casacalenda, Perry, & Looper, 2002; Cipriani et al., 2018). Accordingly, there is an urgent need to gain new insight into the underlying pathophysiology of anxiety and depressive disorders in order to develop more effective treatment targets. The high comorbidity between internalizing disorders has been cited as evidence for possible shared physiological processes, risk factors, and illness trajectories (Kotov et al., 2017). One such promising area of research is the microbiota-gut-brain axis, which may elucidate shared pathophysiology.

A growing body of research describes the bidirectional communication between the gut microbiota – the ecosystem of trillions of bacteria, viruses, archaea and fungi – with the host's central nervous system (CNS; Dinan and Cryan, 2015, Dinan and Cryan, 2017; Rieder, Wisniewski, Alderman, & Campbell, 2017). This biochemical signaling pathway, also known as the gut-brain axis, is thought to influence cognitive functioning and mood via neural, metabolic, hormonal, and immune-mediated mechanisms (Foster & McVey Neufeld, 2013). The gut microbiota is a key regulator within the gut-brain axis: bacterial species regulate the production of neurotransmitters and their precursors (e.g., serotonin, GABA, tryptophan), and can secrete and upregulate essential proteins and metabolites involved in neuropeptide and gut hormone release, such as short-chain fatty acids (SCFAs; e.g., Faecalibacterium prausnitzii and Clostridium leptum) and brain-derived neurotrophic factor (BDNF; e.g., Bifidobacterium; Bercik et al., 2010; O'Sullivan et al., 2011; Parada Venegas et al., 2019). Furthermore, vagal and spinal afferent pathways mediate neural communication between gut microbes and the CNS, and the gut microbiota modulates immune signaling from gut to brain, via cytokine induction (Dinan & Cryan, 2017; Foster, Rinaman, & Cryan, 2017).

The extant literature indicates that gut microbes may also be involved in the development and function of the hypothalamic-pituitary-adrenal (HPA) axis, which coordinates the adaptive stress response in the body (Foster et al., 2017; Sudo et al., 2004). Dysregulated HPA axis signaling is implicated in anxiety and depressive disorders, typically associated with higher levels of cortisol and inflammatory mediators that lead to a sustained proinflammatory state (Keller et al., 2017; Winter, Hart, Charlesworth, & Sharpley, 2018). Not only can the gut microbiota contribute to increases in cortisol and inflammation (Kamada, Seo, Chen, & Núñez, 2013), but proinflammatory states may also compound microbiota alterations via deleterious effects on gastrointestinal health. Excessive levels of circulating cortisol and inflammatory mediators increase intestinal permeability, thus allowing Gram-negative bacteria (i.e., bacteria which contain an additional lipopolysaccharide exterior membrane, associated with inflammation in high concentrations) to translocate into the bloodstream which may induce chronic CNS inflammation (Foster et al., 2017; Huang et al., 2019). This suggests that microbiota-driven inflammatory responses may contribute to affective disorders, due in part to increased intestinal permeability. Similarly, gastrointestinal conditions suspected to involve alterations in the gut microbiota and intestinal permeability co-occur at remarkably high rates with psychiatric disorders (e.g., irritable bowel syndrome; Simpson, Schwartz, & Simmons, 2020). Hence, the role of the gut microbiota in mood regulation and emotional processing, via the gut-brain axis, may be of particular relevance to anxiety and depression aetiology.

Given the role of gastrointestinal bacteria in the bidirectional communication between the gut and the brain, recent studies have focused on characterising gut microbiota composition in anxiety and depression. Preclinical models highlight gut microbiota disturbances in rodents exhibiting anxiety- and depressive-like behaviours, and report normalisation of both behavioural and microbial alterations after bacterial probiotic administration (Mayer, Knight, Mazmanian, Cryan, & Tillisch, 2014; Mayer, Tillisch, & Gupta, 2015). Extension of this research into humans has been relatively slow prior to the last several years. Reviews have highlighted gut microbiota alterations in clinical depressive disorders relative to healthy control groups (Cheung et al., 2019; Huang et al., 2019; Sanada et al., 2020); however, findings related to the diversity of microbial communities in depression are inconsistent, and it is unclear whether specific bacterial taxa drive group differences (Cheung et al., 2019; Huang et al., 2019; Sanada et al., 2020). Existing reviews have also inadequately considered research quality and the effects of confounders, particularly diet and psychotropic medication (Simpson, Schwartz, & Simmons, 2020).

The present systematic review provides an essential update of the expanding literature characterising the gut microbiota in depressive disorders, and provides the first systematic review in anxiety disorders. This paper also aims to integrate evidence to examine whether these highly comorbid conditions share underlying microbial features, and to critically appraise the effect of methodological inconsistencies and confounding factors. A more nuanced understanding of the pathophysiology of anxiety and depressive disorders may inform future diagnosis and treatment options in these common and debilitating psychiatric conditions.

Section snippets

Search strategy

Systematic searches were conducted in March 2020 following PRISMA guidelines (Moher, Liberati, Tetzlaff, Altman, & Group, 2009). The MEDLINE (Ovid), Embase, PsycINFO, and PubMed databases were searched to capture human studies which i) assessed the gut microbiota composition in anxiety or depressive disorders, or ii) investigated associations between the gut microbiota and anxiety/depression symptom measures in healthy participants or relevant conditions (i.e., anxiety and depressive

Characteristics of included studies

Comprehensive screening yielded 1216 studies after duplicate removal (Fig. 1). A total of 26 studies met inclusion criteria, including 17 clinical case-control studies that compared the gut microbiota of controls to participants with a depressive disorder, two studies which compared individuals with generalised anxiety disorder (GAD) to controls, and one study which compared participants with depression, anxiety, or comorbid anxiety/depressive disorder and controls. The remaining six studies

Discussion

The present systematic review provides an essential update of studies characterising the gut microbiota in anxiety and depressive disorders, and captures the large number of studies published in recent years. Of note, the body of literature has nearly doubled since the last systematic review of the gut microbiota in depressive disorders (Cheung et al., 2019). This review also extends a recent summary focused on the gut microbiota in MDD-only (Sanada et al., 2020), by considering depressive

Declaration of Competing Interest

None.

Acknowledgments

Carra Simpson and Djamila Eliby are supported by the Australian Government Research Training Program. Authors thank Ryan Carceller for his assistance with figure design. Figures created with BioRender.com.

Role of funding sources

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Contributors

All authors provided scientific input, and edited and reviewed the manuscript content. All authors provided their final approval and agree to be accountable for all aspects of the work, ensuring integrity and accuracy.

Carra A. Simpson is a PhD Candidate at the University of Melbourne in the Faculty of Medicine Dentistry and Health Sciences (Melbourne School of Psychological Sciences). Her research seeks to bridge the arbitrary categorisation of “mental” and “physical” health. She is passionate about interdisciplinary human microbiome research, specifically the bidirectional relationships between the gut and oral microbiota with host gastrointestinal functioning and behaviour.

References (107)

  • A. Heintz-Buschart et al.

    Human gut microbiome: Function matters

    Trends in Microbiology

    (2018)
  • H. Jiang et al.

    Altered fecal microbiota composition in patients with major depressive disorder

    Brain, Behavior, and Immunity

    (2015)
  • H. Jiang et al.

    Altered gut microbiota profile in patients with generalised anxiety disorder

    Journal of Psychiatric Research

    (2018)
  • J.R. Kelly et al.

    Transferring the blues: Depression-associated gut microbiota induces neurobehavioural changes in the rat

    Journal of Psychiatric Research

    (2016)
  • P. Lin et al.

    Prevotella and Klebsiella proportions in fecal microbial communities are potential characteristic parameters for patients with major depressive disorder

    Journal of Affective Disorders

    (2017)
  • Y. Liu et al.

    Similar Fecal microbiota signatures in patients with Diarrhea-predominant irritable bowel syndrome and patients with depression

    Clinical Gastroenterology and Hepatology

    (2016)
  • J. Loubinoux et al.

    Sulfate-reducing bacteria in human feces and their association with inflammatory bowel diseases

    FEMS Microbiology Ecology

    (2002)
  • B.L. Mason et al.

    Reduced anti-inflammatory gut microbiota are associated with depression and anhedonia

    Journal of Affective Disorders

    (2020)
  • N.D. Nuzum et al.

    Gut microbiota differences between healthy older adults and individuals with Parkinson's disease: A systematic review

    Neuroscience and Biobehavioral Reviews

    (2020)
  • C. Pitsavos et al.

    Anxiety in relation to inflammation and coagulation markers, among healthy adults: The ATTICA study

    Atherosclerosis

    (2006)
  • C.L. Raison et al.

    Cytokines sing the blues: Inflammation and the pathogenesis of depression

    Trends in Immunology

    (2006)
  • R. Rieder et al.

    Microbes and mental health: A review

    Brain, Behavior, and Immunity

    (2017)
  • H. Rong et al.

    Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients

    Journal of Psychiatric Research

    (2019)
  • K. Sanada et al.

    Gut microbiota and majore depressive disorder: A systematic review and meta-analysis

    Journal of Affective Disorders

    (2020)
  • C.A. Simpson et al.

    The human gut microbiota and depression: Widely reviewed, yet poorly understood

    Journal of Affective Disorders

    (2020)
  • R.M. Stilling et al.

    The neuropharmacology of butyrate: The bread and butter of the microbiota-gut-brain axis?

    Neurochemistry International

    (2016)
  • M. Tanaka et al.

    Development of the gut microbiota in infancy and its impact on health in later life

    Allergology International

    (2017)
  • P. Tian et al.

    Bifidobacterium with the role of 5-hydroxytryptophan synthesis regulation alleviates the symptom of depression and related microbiota dysbiosis

    Journal of Nutritional Biochemistry

    (2019)
  • D. Ai et al.

    Identifying gut microbiota associated with colorectal cancer using a zero-inflated lognormal model

    Frontiers in Microbiology

    (2019)
  • J. Andersson

    The inflammatory reflex - introduction

    Journal of Internal Medicine

    (2005)
  • Q.Y. Ang et al.

    Article ketogenic diets alter the gut microbiome resulting in decreased intestinal Th17 cells article ketogenic diets Alter the gut microbiome resulting in decreased intestinal Th17 cells

    Cell

    (2020)
  • J.E. Belizário et al.

    Gut microbiome dysbiosis and immunometabolism: new frontiers for treatment of metabolic diseases

    Mediators of Inflammation

    (2018)
  • P. Bercik et al.

    Chronic gastrointestinal inflammation induces anxiety-like behavior and alters central nervous system biochemistry in mice

    Gastroenterology

    (2010)
  • S.C. Bischoff et al.

    Intestinal permeability--a new target for disease prevention and therapy

    BMC Gastroenterology

    (2014)
  • J.G. Caporaso et al.

    QIIME allows analysis of high-throughput community sequencing data

    Nature Methods

    (2010)
  • N. Casacalenda et al.

    Remission in major depressive disorder: A comparison of pharmacotherapy, psychotherapy, and control conditions

    American Journal of Psychiatry

    (2002)
  • J. Chen et al.

    Sex differences in gut microbiota in patients with major depressive disorder

    Neuropsychiatric Disease and Treatment

    (2018)
  • Z. Chen et al.

    Comparative metaproteomics analysis shows altered fecal microbiota signatures in patients with major depressive disorder

    NeuroReport

    (2018)
  • S. Cheng et al.

    Identifying psychiatric disorder-associated gut microbiota using microbiota-related gene set enrichment analysis

    Briefings in Bioinformatics

    (2019)
  • S.G. Cheung et al.

    Systematic review of gut microbiota and major depression

    Frontiers in Psychiatry

    (2019)
  • C. De Filippo et al.

    Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa

    Proceedings of the National Academy of Sciences

    (2010)
  • S. Devkota et al.

    Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10−/− mice

    Nature

    (2012)
  • T.G. Dinan et al.

    The impact of gut microbiota on brain and behaviour: Implications for psychiatry

    Current Opinion in Clinical Nutrition and Metabolic Care

    (2015)
  • T.G. Dinan et al.

    Brain-gut-microbiota axis and mental health

    Psychosomatic Medicine

    (2017)
  • C.M. Doran et al.

    A review of the economic impact of mental illness

    Australian Health Review

    (2019)
  • H.J. Flint et al.

    Microbial degradation of complex carbohydrates in the gut

    Gut Microbes

    (2012)
  • J.A. Foster et al.

    Stress & the gut-brain axis: Regulation by the microbiome

    Neurobiol. Stress.

    (2017)
  • J. Gerritsen et al.

    Intestinal microbiota in human health and disease: The impact of probiotics

    Genes Nutrition

    (2011)
  • D. Gong et al.

    Involvement of reduced microbial diversity in inflammatory bowel disease

    Gastroenterology Research and Practice

    (2016)
  • N. Heym et al.

    The role of microbiota and inflammation in self-judgement and empathy: Implications for understanding the brain-gut-microbiome axis in depression

    Psychopharmacology

    (2019)
  • Cited by (381)

    View all citing articles on Scopus

    Carra A. Simpson is a PhD Candidate at the University of Melbourne in the Faculty of Medicine Dentistry and Health Sciences (Melbourne School of Psychological Sciences). Her research seeks to bridge the arbitrary categorisation of “mental” and “physical” health. She is passionate about interdisciplinary human microbiome research, specifically the bidirectional relationships between the gut and oral microbiota with host gastrointestinal functioning and behaviour.

    Carmela Díaz-Arteche is a Research Assistant at the University of Melbourne in the Faculty of Medicine Dentistry and Health Sciences (Melbourne Neuropsychiatry Centre). Her research interests include investigating associations between neurodevelopment and affective disorders.

    Djamila Eliby is a PhD Candidate at the University of Melbourne in the Faculty of Medicine Dentistry and Health Sciences (Melbourne School of Psychological Sciences). Her research interests include investigating associations between the gut microbiome, mental health, and diet.

    Orli S. Schwartz is a Clinical Psychologist and a Research Fellow in Mood Disorders at Orygen, the Centre for Youth Mental Health at the University of Melbourne Faculty of Medicine Dentistry and Health Sciences.

    Julian G. Simmons is a Senior Research Fellow at the University of Melbourne in the Faculty of Medicine Dentistry and Health Sciences (Melbourne School of Psychological Sciences). His research focusses on how the environments we grow up in interact with our biology to influence risk (and protection) for mental health disorders, and particularly depressive and anxiety disorders.

    Caitlin S. M. Cowan is a Post-Doctoral Research Fellow at the APC Microbiome Ireland, University College Cork. She is a clinically-trained psychologist and behavioural neuroscientist with a special interest in development. Her research explores the translational value of targeting the brain-gut axis to modulate behavioural and mental health outcomes.

    1

    Joint senior authorship.

    View full text